News

Avammune Therapeutics raises $12 million to advance cancer therapies

Publications

Small molecule innate immune modulators in cancer therapy
Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Barnali Deb, Aditya Kulkarni

PMID: 39318624 PMCID: PMC11419979 DOI:10.3389/fimmu.2024.1395655

AVA-ADR-001 Suppresses Tumor Growth and Induces Anti-tumor Immunity by Selectively Inhibiting ADAR1 p150
Aditya Kulkarni, Avijit Goswami, Barnali Deb, Ankita Mohanty, Sandeep Goyal, Kawaljit Singh, Rahul Yadav, Princy Khurana, Narenkumar Muralidharan, Jan Rehwinkel

Molecules 2022,27(19), 6721; DOI: 10.3390/molecules27196721

Conference Abstracts

Abstract 4484: Discovery of a potential first-in-class Za targeted small molecule inhibitor of ADAR1 p150 which demonstrates strong anti-tumor efficacy
Avijit Goswami, Sandeep Goyal, Kawaljit Singh, Princy Khurana, Barnali Deb, Aditya Kulkarni

Journal: Cancer Research Cancer Res (2024) 84 (6_Supplement): 4484. https://doi.org/10.1158/1538-7445.AM2024-4484

864 AVA-NP-695, a potent and selective ENPP1 inhibitor, demonstrates strong anti-tumor efficacy as monotherapy and in combination with radiation
Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Ishani Ghoshal, Aditya Kulkarni

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A963; DOI:10.1136/jitc-2023-SITC2023.0864

Reach out to us

→

USA

Avammune Therapeutics, Inc. Pennsylvania

India

Avammune Lifesciences Private Limited #545/6, 1st Floor, Devarachikkanahalli Main Road, Bommanahalli, Bangalore 560068
080-41268499
© 2026 Avammune Therapeutics